Immunotherapy in Cancer Treatment: A New Era of Hope

Understanding its role in Breast Cancer at Different Stages: Cancer treatment has evolved dramatically over the past decade. Among the most promising advancements is immunotherapy — a treatment that uses the body’s own immune system to recognize and destroy cancer cells. Normally, our immune system is highly skilled at identifying anything that does not belong in the body. However, cancer cells can cleverly hide and suppress the immune response. Immunotherapy helps the immune system wake up, find cancer cells, and attack them more effectively. This approach is different from chemotherapy or targeted therapy, which directly act on cancer cells. Instead, immunotherapy gives power back to the body’s natural defense system. Immunotherapy drugs work by re-activating the immune system’s ability to recognize and eliminate cancer cells. Tumors often evade immune destruction by exploiting regulatory pathways such as immune checkpoints — for example, PD-1/PD-L1 and CTLA-4 — which normally function to prevent excessive immune activation. Checkpoint inhibitor immunotherapies are monoclonal antibodies that block these inhibitory receptors or ligands, thereby releasing the “brakes” on cytotoxic T cells and allowing them to attack malignant cells more efficiently. Other forms of immunotherapy include CAR-T cell therapy, in which a patient’s T cells are genetically engineered to express specific receptors targeting tumor antigens, and cancer vaccines, which stimulate adaptive immune memory against tumor-associated markers. Additionally, cytokine-based treatments and immune stimulators enhance immune cell proliferation and activity within the tumor microenvironment. Together, these strategies aim to overcome tumor-induced immune suppression, achieve durable antitumor responses, and establish long-term immunologic surveillance to prevent relapse.

How Does Immunotherapy Work? Immunotherapy works in several ways, such as:

  • Checkpoint inhibitors: Cancer cells often use “brakes” on the immune system to avoid attack. These drugs release those brakes so immune cells can act freely.
  • Immunomodulators: They boost the overall activity of the immune system.
  • Cell-based therapies: Immune cells are enhanced or engineered outside the body and then infused back to target cancer more strongly.
  • Cancer vaccines: These help the body recognize cancer-specific markers and develop long-term defense.
  • These treatments have already improved outcomes in melanoma, lung cancer, kidney cancer, and many others.

 

Immunotherapy in Breast Cancer: Breast cancer is a very diverse disease, with different biological subtypes. Immunotherapy is becoming particularly valuable in Triple-Negative Breast Cancer (TNBC) — a type that lacks hormone receptors and HER2 expression and tends to be more aggressive.

Here’s how immunotherapy fits into different stages of breast cancer:

1.        Early-Stage Breast Cancer

  • For patients with high-risk early-stage TNBC, immunotherapy is now used in combination with chemotherapy before surgery.
  • This approach increases the chance of completely eliminating cancer in the breast and lymph nodes.
  • It may also reduce risk of recurrence in the future.

 

2.       Locally Advanced Breast Cancer

  • When the tumor is large or has spread to nearby nodes, but not distant organs, immunotherapy plus chemotherapy can shrink the cancer.
  • This helps make surgery more successful and improves long-term outcomes.

 

3.       Metastatic / Stage IV Breast Cancer

  • Immunotherapy has shown meaningful benefit in patients whose TNBC expresses PD-L1, an immune-checkpoint marker.
  • It can help control cancer for longer, maintain better quality of life, and may extend survival.
  • In some selected patients, tumors shrink significantly, making ongoing treatment more manageable.

 

Why Immunotherapy Matters

  • More personalized treatment based on cancer biology
  • Better tolerance for many patients compared to traditional chemotherapy
  • Long-lasting immune memory, which can help keep cancer away even after treatment stops

 

It represents a major shift—from only attacking cancer to empowering the immune system to stay vigilant.

Side Effects of Immunotherapy in Breast Cancer Patients

Immunotherapy generally has a different side-effect profile compared to chemotherapy. Because it activates the immune system, the most common reactions come from the immune system attacking healthy tissues — these are called immune-related adverse events (irAEs).

Some commonly seen side effects include:

  • Skin reactions Rash, itching, dryness, or changes in skin color. These are usually mild and manageable with creams or medicines.
  • Fatigue A common effect that can vary from mild tiredness to more significant weakness.
  • Gastrointestinal symptoms Diarrhea or inflammation of the bowel (colitis) can occur in some patients.
  • Hormone gland inflammation the thyroid, adrenal glands, or pituitary gland can get affected, leading to hormonal imbalance. Symptoms may include weight changes, hair loss, mood changes, or low energy, often requiring hormone replacement.
  • Lung inflammation (pneumonitis) Causes cough, breathlessness, or chest discomfort. This needs prompt medical attention.
  • Liver inflammation (hepatitis) Usually detected by blood tests before symptoms appear.

 

While many side effects are mild, some can be serious if not addressed early. The good news is that most irAEs respond very well to timely treatment, especially with corticosteroids or temporary pause of immunotherapy.

Why monitoring matters: During immunotherapy, patients are closely followed with regular check-ups and blood tests. Any new symptom — even if small — should be reported early so that doctors can act quickly and prevent complications. With proper monitoring, most patients continue treatment safely and benefit from its long-term effects.

Common Immunotherapy Drugs Used in Breast Cancer

At present, immunotherapy in breast cancer is mainly focused on Triple-Negative Breast Cancer (TNBC). The most commonly used drug is Pembrolizumab, a checkpoint inhibitor that targets the PD-1 receptor on immune cells. By blocking this receptor, the medicine allows T-cells to recognize and attack cancer cells more effectively. Pembrolizumab is now approved for use in early-stage high-risk TNBC along with chemotherapy before surgery, as well as in metastatic TNBC where the tumor expresses the PD-L1 marker. Another drug used in selected metastatic TNBC cases is Atezolizumab, which targets the PD-L1 protein on cancer cells and immune cells. These medicines have shown meaningful benefits in controlling disease and improving long-term outcomes in eligible patients.

The Road Ahead: Research is rapidly progressing to:

  • Expand immunotherapy beyond TNBC to other breast cancer subtypes
  • Identify which patients benefit the most
  • Improve combinations with targeted therapy, hormone therapy, and radiation
  • Immunotherapy is not yet for all breast cancer patients, but it is a strong and growing pillar of modern cancer care.
  • Landmark Trials in Immunotherapy for Breast Cancer

 

Landmark trials related to the immunotherapy in breast cancer: The introduction of immunotherapy in breast cancer has been driven by major clinical trials, particularly in triple-negative breast cancer (TNBC). The KEYNOTE-522 trial was a breakthrough in early-stage disease, showing that adding pembrolizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response and improved event-free survival, leading to global approval for high-risk early TNBC. In metastatic settings, KEYNOTE-355 demonstrated that pembrolizumab combined with chemotherapy offered a meaningful survival benefit in PD-L1 positive metastatic TNBC, establishing it as a standard first-line option. Another key trial, IMpassion130, evaluated atezolizumab with nab-paclitaxel in metastatic TNBC and showed improved progression-free survival in PD-L1 positive patients, marking the first immunotherapy approval in advanced breast cancer. Although later trials such as IMpassion131 did not replicate the same benefit, the collective evidence from these pivotal studies has opened a new and hopeful chapter, integrating immunotherapy as an important treatment pillar in selected breast cancer patients.

Final Takeaway:

  • These drugs are not for all breast cancers — they benefit patients whose tumors show PD-L1 expression and are mostly used in TNBC.
  • They are often combined with chemotherapy for better effectiveness.
  • Selection of patients is done using specialized biomarker testing.

 

Immunotherapy has opened a new chapter in breast cancer treatment — one filled with innovation, hope, and better outcomes. As research continues, more patients will have access to this powerful and personalized strategy to fight cancer.

#breastcancer #TNBC #immunotherapyforbreastcancer #breastcancersurvival